Skip to main content

Table 4 Results of Cox regression analysis*

From: Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas

Covariate

Hazard function** (95% confidence intervals)

p-value

Age

1.01 (1.00, 1.02)

.006

Prior chemotherapy

1.02 (0.92, 1.14)

.659

Group B

0.48 (0.35, 0.66)

<.0001

Group C

0.51 (0.40, 0.65)

<.0001

  1. *Analysis was performed using treatment groups A through C as a categorical indicator and Group A as the reference.
  2. **Hazard function if less than 1 it indicates increased PFS and, if greater than 1 decreased PFS. In the case above, Groups B+C are associated with statistically increased PFS.